About this program

This program aims at developing an anti-CD39 antibody for immuno-oncology. By targeting the adenosine immunosuppressive pathway, it has the potential to promote anti-tumor immune responses across a wide range of tumors.

CD39 is a membrane-bound extracellular enzyme overexpressed on both regulatory T cells and several cancer types. It plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression and dysregulation of immune cell infiltrates resulting in tumor spreading. Blockade of CD39 may therefore stimulate anti-tumor immunity across a wide range of tumors (including kidney, lung, ovarian, pancreatic, thyroid, testicular, endometrial, and prostate tumors, as well as in lymphoma and melanoma) by preventing the production of immunosuppressive adenosine and by promoting the accumulation of ATP in the tumor microenvironment.

Mechanism of action of IPH5201 (anti-CD39)

In October 2018, Innate Pharma and AstraZeneca entered into a development collaboration and option agreement for further co-development and co-commercialization for IPH5201.

The multicenter, open-label, dose-escalation Phase I study will evaluate the safety, tolerability, antitumor activity, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of IPH5201 alone, or in combination with AstraZeneca‚Äôs anti-programmed cell death ligand 1 (PD-L1) therapy, durvalumab, with or without its anti-CD73 monoclonal antibody, oleclumab.  More information on the  Phase I clinical trial can be found at
https://clinicaltrials.gov/ct2/show/NCT04261075.